Liprolog (Insulin Lispro)

Insulin lispro has a slightly altered amino‑acid sequence that prevents it from forming hexamers, allowing it to be absorbed rapidly after injection. It binds to insulin receptors, activates intracellular pathways that increase glucose uptake into muscle and fat cells, and suppresses liver glucose production, producing a fast decline in blood sugar.

The dose of Liprolog is individualized by the prescribing healthcare professional. It is based on factors such as the patient’s current blood‑glucose levels, carbohydrate intake, activity level, and overall diabetes management plan. Patients should follow the prescriber’s instructions and adjust only under medical guidance.

Safety data for insulin lispro in pregnancy and lactation are limited. It may be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision. Breastfeeding mothers should consult their healthcare provider before starting or continuing therapy.

To order Liprolog, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Liprolog (insulin lispro) shares the rapid onset and short duration characteristic of rapid‑acting analogues such as insulin aspart and insulin glulisine. Its slightly altered structure provides faster absorption than regular human insulin, offering comparable efficacy and safety profiles, with choice often guided by clinician preference, patient response, and formulary considerations.

Liprolog should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at controlled room temperature (up to 25 °C) for a maximum of 28 days, but any unused portion should be discarded after that period.

Liprolog is supplied as a clear solution for injection and can be given subcutaneously or intravenously. Subcutaneous injections are typically performed in the abdomen, thigh, or upper arm using a short‑acting needle. Intravenous administration is reserved for hospital settings, such as during surgery or acute glucose control.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rarely, patients may develop insulin antibodies that diminish the drug’s effectiveness. Prompt recognition and treatment of these events are essential.

Liprolog should be avoided in individuals with a known hypersensitivity to insulin lispro or any of the excipients in the formulation. It is also contraindicated in patients with severe hypoglycemia unawareness or those who cannot reliably monitor blood glucose and adjust dosing under medical supervision.